Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase.

Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Matzke M, Pleiss U, Keldenich J, Müller-Peddinghaus R.

Agents Actions. 1994 Nov;43(1-2):64-8. Review.

PMID:
7741044
2.

Ca2+ ionophore A23187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene B4.

Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R.

Biochem Pharmacol. 1994 Jul 5;48(1):31-9.

PMID:
8043028
3.
4.

(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways.

Gorenne I, Labat C, Gascard JP, Norel X, Müller-Peddinghaus R, Mohrs KH, Taylor WA, Gardiner PJ, Brink C.

J Pharmacol Exp Ther. 1994 Feb;268(2):868-72.

PMID:
8114000
5.

Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X1005. Implications for biological regulation of 5-lipoxygenase.

Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Matzke M, Pleiss U, Keldenich J, Müller-Peddinghaus R.

Adv Prostaglandin Thromboxane Leukot Res. 1994;22:23-31. Review. No abstract available.

PMID:
7771337
6.

BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.

Müller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P, Fruchtmann R, Perzborn E, Beckermann B, Bühner K, Ahr HJ, Mohrs KH.

J Pharmacol Exp Ther. 1993 Oct;267(1):51-7.

PMID:
8229782
7.

In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis.

Fruchtmann R, Mohrs KH, Hatzelmann A, Raddatz S, Fugmann B, Junge B, Horstmann H, Müller-Peddinghaus R.

Agents Actions. 1993 Mar;38(3-4):188-95.

PMID:
8213345
8.

Supplemental Content

Loading ...
Support Center